Recent study presented at #SITC25 using novel mouse models of aging to investigate the effects of aging on specific T cell populations, anti-cancer immunity, and cancer metastasis. Results provide insights on new age-specific therapeutic strategies and targets to treat metastatic disease in elderly patients with cancer. Read this excellent study in #JITC: jitc.bmj.com/content/13/Supp…

Preclinical study presented at #SITC25! Exciting innovative approach using advanced genetic engineering techniques to edit healthy, non-cancerous B cells so they are no longer recognized by CD19-targeting CAR T cells. View more: dx.doi.org/10.1136/jitc-2025…

New insights to best practices in combining radiotherapy and immunotherapy for head and neck cancers presented at #SITC25! This translational study features a novel mouse reporter model to track the migration of immune cells between the tumor and lymph nodes. Explore more: jitc.bmj.com/content/13/Supp…

Presented at #SITC25: exciting novel approach in which monocytes are genetically engineered with CARs to recognize and destroy immunosuppressive tumor associated macrophages in breast cancer. Learn more: jitc.bmj.com/content/13/Supp…

As a cellular therapies session is underway at #SITC25, explore more on KLF2 expression with this recent #JITC paper from Ruben Prins et al of the University of Southern California, Los Angeles: jitc.bmj.com/content/13/8/e0…

Just presented at #SITC25: a study that indicates that the COVID vaccine, an mRNA vaccine that does not target cancer antigens, is associated with enhanced response to immunotherapy and suggests that mRNA vaccines in general may activate immune cells and promote anti-cancer immunity. Read this study: jitc.bmj.com/content/13/Supp… @adam_grippin

Adam Schoenfeld presents ”Initial Phase 1a/1b Results of STK-012, an α/β IL-2 Receptor Biased Partial Agonist, with Pembrolizumab, Pemetrexed, and Carboplatin in 1L PD-L1 Negative Non-Squamous NSCLC” at #SITC25. Explore more on novel target agonist with an insightful report from Patrizia Murer et al of ANAVEON AG: jitc.bmj.com/content/13/7/e0…

Translational study on the role of myeloperoxidase just presented at #SITC25! This study can potentially identify new therapeutic targets for pancreatic cancer and other immunosuppressive, immunologically "cold" tumors. View this study: jitc.bmj.com/content/13/Supp…

#ICYMI: Young Kwang Chae, MD, MPH, MBA, PhD presents, “QVT Score, a radiomic biomarker of tumor vascularity, enables immune checkpoint inhibitor (ICI) outcome prediction and early survival assessment in NSCLC” at #SITC25. Dive into more biomarker research with a promising #JITC manuscript from Guanchoa Ye et al of The First Affiliated Hospital of Zhengzhou University. jitc.bmj.com/content/12/9/e0…

At #SITC25, Jalal Ahmed, MD, PhD reports how “Dendritic cells accelerate CAR T cells in irradiated tumors through chimeric synapses”. Discover more CAR-T insights from Kun Wang et al of Cedars-Sinai Medical Center in this recent #JITC paper: jitc.bmj.com/content/13/1/e0…

As Rosa Nadal Rios, MD, PhD presents, “Immune cell composition analysis of ERVE-4 T-cell receptor gene therapy infusion products in metastatic ccRCC: Insights from a first-in-human trial” at #SITC25, explore more on T cell receptor-engineered T cells. View this powerful piece in #JITC from Stefan Barisic et al of the National Institutes of Health. jitc.bmj.com/content/12/4/e0…

Great work coming out of #SITC25! Li Zhang presents, “Final Overall Survival Analysis of HARMONi-A Study Comparing Ivonescimab Plus Chemotherapy to Chemotherapy Alone in Patients With EGFR+ NSCLC Progressed on EGFR-TKI Treatment” during a clinical oral abstract session. Access more ivonescimab research with this recent paper in #JITC from Sophia Frentzas et al of Monash Health: jitc.bmj.com/content/12/4/e0…

New #JITC review: Chimeric antigen receptor (CAR) T-cell therapy for glioblastoma (GBM): current clinical insights, challenges, and future directions jitc.bmj.com/content/13/10/e…

New #JITC review: High-risk neuroblastoma as a model for immunotherapy of non-immunogenic cancers: where might we be in 20 years?

New #JITC article: Perioperative pembrolizumab in early-stage non-small cell lung cancer (NSCLC): conventional and distribution-based immune profiling of the tumor microenvironment and peripheral circulation jitc.bmj.com/content/13/10/e…

New #JITC article: Stress-NRF2 response axis polarizes tumor macrophages and undermines immunotherapy jitc.bmj.com/content/13/10/e…

New #JITC article: Systemic immunosuppression from ultraviolet radiation exposure inhibits cancer immunotherapy jitc.bmj.com/content/13/10/e…

Development & Validation of The Immune Profile Score (IPS), a Novel Multiomic Algorithmic Assay For Stratifying Outcomes in a Real-World Cohort of Pts w/ Adv Solid Cancer Tx'd w/ Immune Checkpoint Inhibitors [May 30, 2025] Zander etal @jitcancer tempus.com/publications/deve… #ImmunoOnc

🎯 To broaden the range of tumor-restricted antigens, researchers developed CAR T cells targeting Tenascin-C, a secreted extracellular matrix protein that is overexpressed in glioblastomas and plays a critical role in tumor progression. @jitcancer | bit.ly/47txHTC

The 2025 #JITC Best Oncolytic and Local Immunotherapy Paper focuses on the role of therapeutic agents designed for targeting tumor cells. Read this excellent manuscript for the latest on oncolytic viruses, microbial agents, and more! jitc.bmj.com/content/13/6/e0… #SITC25